

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



July 19, 2018

### **New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hereditary Angioedema**

Effective August 6, 2018, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will be adding a PA with QL for agents for prophylaxis and/or acute attacks of hereditary angioedema.

The intent of the Hereditary Angioedema PA program is to ensure that patients' prescribed therapy meet the selection requirements defined in product labeling and/or clinical guidelines and/or clinical studies. The PA defines appropriate use as the Food and Drug Administration (FDA) labeled indication or as supported by guidelines and/or clinical evidence. Agents approved to treat acute hereditary angioedema attacks used in combination for acute hereditary angioedema attacks will not be supported.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence-based care. One method for doing so is through the PA process. The primary purpose of the PA process is to ensure that evidence-based care is provided to our subscribers, driving quality, safety, and affordability.

<b>Hereditary Angioedema PA with QL</b>	<b>Quantity Limit</b>
BERINERT <sup>®</sup> (C1 esterase inhibitor, [human])	5,000 units (10 vials) / 30 days
CINRYZE <sup>®</sup> (C1 esterase inhibitor, [human])	10,000 units (20 vials) / 30 days
FIRAZYR <sup>®</sup> (icatibant)	180 mg (6 syringes) / 30 days
HAEGARDA <sup>®</sup> (C1 esterase inhibitor)	2000 units 16 vials / 28 days 3000 units 16 vials / 28 days
KALBITOR <sup>®</sup> (ecallantide)	120 mg (4 kits) / 30 days
RUCONEST <sup>®</sup> (C1 esterase inhibitor, [recombinant])	16,800 units (8 vials) / 30 days

### **Products Impacted**

This PA program applies to commercial lines of business.

Continued

QP57-18

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Blue Cross<sup>®</sup> and Blue Shield<sup>®</sup> of Minnesota and Blue Plus<sup>®</sup> are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

L264R03 (12/13)

To view the pharmacy policy, please visit the Blue Cross provider link.

- Access **providers.bluecrossmn.com**
- Under Tools and Resources, select “Medical Policy”, then acknowledge the Acceptance statement
- Select Medical and Behavioral Health Policies
- Select Blue Cross and Blue Shield of Minnesota Medical Policies

Providers can submit an electronic drug prior authorization (ePA) request through one of the following:

- Online via our free [Availity](#) provider portal – for Blue Cross to review
- Using a [NCPDP](#) standard XML file feed to Blue Cross through CenterX, via an integrated Electronic Medical Record (EMR) system. To learn how to do this, providers should contact their EMR vendor for assistance.
- Out of state, non-contracted providers can submit a PA request to Blue Cross by either using the electronic processes above, the [Minnesota Uniform Form for Prescription Drug PA Request and Formulary Exceptions](#) fax form located under the Forms section on the Blue Cross website, or their own PA form (secure fax: 651.662.2810).

### **Questions?**

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.